help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2009-0058
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Yeung, D. C. Y.
Right arrow Articles by Xu, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yeung, D. C. Y.
Right arrow Articles by Xu, A.
Related Collections
Right arrow Lipid
Right arrow Diabetes and Insulin
Right arrow Metabolism
Right arrow Obesity
The Journal of Clinical Endocrinology & Metabolism Vol. 94, No. 7 2531-2536
Copyright © 2009 by The Endocrine Society

Serum Zinc-{alpha}2-Glycoprotein Correlates with Adiposity, Triglycerides, and the Key Components of the Metabolic Syndrome in Chinese Subjects

Dennis C. Y. Yeung, Karen S. L. Lam, Yu Wang, Annette W. K. Tso and Aimin Xu

Department of Medicine (D.C.Y.Y., K.S.L.L., A.W.K.T., A.X.), The Research Center of Heart, Brain, Hormone and Healthy Ageing (K.S.L.L., Y.W., A.W.K.T., A.X.), and Department of Pharmacology (Y.W., A.X.), The University of Hong Kong, Hong Kong SAR, China

Address all correspondence and requests for reprints to: Dr. Aimin Xu or Prof. Karen S. L. Lam, Department of Medicine, The University of Hong Kong, L8-43, Laboratory Block, 21 Sassoon Road, Hong Kong SAR, China. E-mail: amxu{at}hkucc.hku.hk or ksllam{at}hkucc.hku.hk.

Context: Zinc-{alpha}2-glycoprotein (ZAG) is a 40-kDa circulating glycoprotein secreted from the liver and adipose tissues. Animal studies have demonstrated the role of ZAG as a lipid-mobilizing factor involved in regulating lipid metabolism and adiposity. However, the clinical relevance of these findings remains to be established.

Objective: This study aimed to address the relationship of serum ZAG levels with adiposity and cardiometabolic risk factors in humans.

Design and Setting: A total of 258 Chinese subjects [aged 55.1 ± 12.5 yr; 120 males, 138 females; body mass index (BMI), 25.4 ± 4.1 kg/m2] were randomly selected from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study, based on their BMI. Serum ZAG levels were determined with ELISA. The relationship between serum ZAG levels and cardiometabolic parameters was assessed.

Results: Serum ZAG levels were higher in men (P < 0.001 vs. women). Serum ZAG correlated positively with age, parameters of adiposity (waist circumference and BMI), fasting insulin, insulin resistance indices, serum triglycerides, adipocyte-fatty acid-binding protein, and C-reactive protein, and diastolic blood pressure (all P < 0.005, age- and sex-adjusted), and inversely with high-density lipoprotein-cholesterol levels (P = 0.008, age- and sex-adjusted). It was also elevated progressively with an increasing number of components of the metabolic syndrome (P for trend < 0.001). On multivariate analysis, serum ZAG was independently associated with male sex, the metabolic syndrome (or type 2 diabetes and serum triglycerides), and C-reactive protein (all P ≤ 0.002).

Conclusions: ZAG might be involved in the pathogenesis of obesity-related metabolic disorders in humans and thus warrants further investigation.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society